• Kir2.1 Inhibition in Pulmonary Vascular Remodeling

  2026-09-21

  The reference study identifies KIR2.1 as a functional regulator of pulmonary artery smooth muscle cell proliferation and migration, linking this channel to TGF-β1/SMAD2/3 signaling and pulmonary vascular remodeling. Its combined rat model and human-cell experiments show how pharmacological inhibition can reduce pathological PASMC behavior, while also highlighting the need for genetic and translational validation.

• JNJ-10198409: PDGF Receptor Inhibitor

  2026-09-21

  JNJ-10198409 is a platelet-derived growth factor receptor inhibitor that competitively targets the ATP-binding site of the PDGF-BB receptor. Its reported 4.2 nM IC50 in human coronary artery smooth muscle cells supports use as a research tool for PDGF-driven proliferation, migration, angiogenesis, and fibrosis-related assays.

• In Vitro Embryonic Dormancy Through mTOR Inhibition

  2026-09-20

  The Nature Protocols study converts pharmacologically induced mTOR inhibition into a reproducible in vitro framework for placing mouse blastocysts, human blastoids, and mammalian pluripotent stem cells into a reversible, diapause-like state. Its main contribution is a scalable, noninvasive platform for analyzing developmental pausing, reactivation, and embryonic competence without relying on surgery-based models.

• Lactate–GPR81 Signaling Enables Insulin-Independent Uptake

  2026-09-19

  A 2026 Cell Research study identifies lactate as an insulin-independent regulator of skeletal-muscle glucose uptake and defines a GPR81–FARP1–RAC1 pathway that promotes GLUT4 translocation. The findings connect exercise-associated lactate production with glucose control and suggest that GPR81 may complement, rather than replace, insulin signaling in metabolic disease research.

• Formononetin and Oxaliplatin Neurotoxicity

  2026-09-18

  A 2026 NeuroToxicology study identifies formononetin as a potential neuroprotective agent against oxaliplatin-induced peripheral neurotoxicity in sensory neuron models. The compound activated the Nrf2/HO-1 antioxidant pathway, reduced oxidative stress and apoptosis, and preserved oxaliplatin and paclitaxel anticancer activity in cultured tumor cells, although protection against paclitaxel-related neurite damage was limited.

• Perospirone Inhibits Vascular Kv1.5 Channels

  2026-09-18

  A 2025 Journal of Applied Toxicology study identifies a previously unrecognized electrophysiological action of Perospirone in freshly isolated rabbit coronary arterial smooth muscle cells. The drug inhibited vascular voltage-gated K+ currents in a concentration-dependent, use-independent manner, with pharmacological evidence implicating Kv1.5 channels and raising questions about cardiovascular effects beyond its established antipsychotic mechanism.

• Anlotinib hydrochloride: Angiogenesis Workflows

  2026-09-17

  Build mechanism-led angiogenesis experiments around Anlotinib hydrochloride, from receptor phosphorylation to endothelial migration and tube formation. This practical guide combines dose selection, pathway validation, comparative controls, and troubleshooting for reproducible cancer research.

• Masitinib (AB1010) Workflow Guide

  2026-09-17

  Masitinib (AB1010), SKU A2942, provides a DMSO-compatible research tool for focused KIT, PDGFRα, and PDGFRβ inhibition in cellular, biochemical, mast-cell, and cancer models. It is not appropriate for aqueous or ethanol-based workflows, broad-spectrum kinase profiling, or clinical dosing decisions without separate validation.

• 10 mM dNTP Mixture: From PCR Input to Assay Control

  2026-09-16

  The 10 mM dNTP mixture is more than a convenient PCR reagent: its defined composition can function as a control point in DNA synthesis and nucleic-acid assay design. This article connects nucleotide standardization with intracellular trafficking research while clearly separating supported evidence from practical workflow recommendations.

• CP-673451: Biomarker-Aware PDGFR Research

  2026-09-16

  CP-673451 is a selective PDGFRα/β inhibitor for dissecting receptor signaling, angiogenesis, and tumor biology. This guide develops a biomarker-aware assay strategy that connects PDGFR pharmacology with ATRX-deficient glioma research without overstating translational evidence.

• CLCC1 and Herpesvirus Nuclear Egress Fusion

  2026-09-15

  A 2024 bioRxiv preprint identifies the host factor CLCC1 as essential for the membrane-fusion step of herpes simplex virus 1 nuclear egress. The study separates viral NEC-driven budding from host-dependent fusion and connects herpesvirus capsid export with nuclear pore complex membrane insertion, providing a framework for investigating host-controlled stages of infection.

• Thiamet G Workflow for O-GlcNAc Studies

  2026-09-15

  Thiamet G provides a controlled way to elevate protein O-GlcNAcylation in cell, disease, and mechanistic assays. This workflow connects tauopathy research and leukemia studies with a carefully bounded extension into trophoblast ferroptosis and preeclampsia research.

• EZ Cap™ OVA mRNA: Designing Interpretable Immune Assays

  2026-09-14

  Learn how EZ Cap™ OVA mRNA can function as a standardized antigen-expression input for separating delivery performance, protein expression enhancement, and inflammatory biology. This article connects assay design to recent low-inflammation mRNA delivery research while emphasizing practical controls and interpretation.

• Inducing Right Ventricular-Like Cardiomyocytes from hPSCs

  2026-09-14

  Saito et al. developed a differentiation strategy that shifts human pluripotent stem cell cardiac progenitors toward an anterior second heart field-like state and produces right ventricular-like cardiomyocytes. The resulting cells differed from left ventricular-like controls in gene expression, spontaneous contraction, calcium handling, and cell size, providing a useful framework for chamber-specific disease modeling.

• BEND Lipids Improve mRNA Delivery and Gene Editing

  2026-09-13

  The reference study introduces branched endosomal disruptor lipids that improve lipid nanoparticle delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes. By linking terminal branching to enhanced endosomal penetration, the work provides a rational design strategy for hepatic gene editing and T-cell engineering.

8464 records 1/565 page Next 12345 下5页 Last page